Skip to Content
Merck
  • A New Histone Deacetylase Inhibitor Enhances Radiation Sensitivity through the Induction of Misfolded Protein Aggregation and Autophagy in Triple-Negative Breast Cancer.

A New Histone Deacetylase Inhibitor Enhances Radiation Sensitivity through the Induction of Misfolded Protein Aggregation and Autophagy in Triple-Negative Breast Cancer.

Cancers (2019-11-07)
Hui-Wen Chiu, Ya-Ling Yeh, Sheng-Yow Ho, Yuan-Hua Wu, Bour-Jr Wang, Wei-Jan Huang, Yuan-Soon Ho, Ying-Jan Wang, Li-Ching Chen, Shih-Hsin Tu
ABSTRACT

Radiation therapy (RT) is one of the main treatments for triple-negative breast cancer (TNBC). However, many patients experience RT failure due to the metastatic potential of RT and the radiation resistance of several cancers. Histone deacetylase inhibitors (HDACis) can serve as radiosensitizers. In this study, we investigated whether a novel HDACi, TMU-35435, could reinforce radiosensitivity through the induction of misfolded protein aggregation and autophagy in TNBC. Significantly enhanced toxicity was found for the combination treatment compared with TMU-35435 or irradiation (IR) treatment alone in TNBC cells. The combination treatment induced misfolded protein aggregation and TMU-35435 inhibited the interaction of HDAC6 with dynein. Furthermore, the combined treatment induced endoplasmic reticulum (ER) stress but did not trigger apoptosis. In addition, the combination treatment caused autophagic cell death. Tumor growth in the mouse of model orthotopic breast cancer was suppressed by the combination treatment through the induction of ER stress and autophagy. These findings support the future evaluation of the novel HDACi TMU-35435, as a potent radiosensitizer in TNBC.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Acridine Orange hydrochloride solution, 10 mg/mL in H2O, >95.0% (HPLC)
Sigma-Aldrich
MISSION® esiRNA, targeting human HDAC6